Difference between revisions of "DANA-FARBER CANCER INSTITUTE, INC. patent applications published on March 21st, 2024"
Jump to navigation
Jump to search
Wikipatents (talk | contribs) (Creating a new page) |
Wikipatents (talk | contribs) |
||
| (6 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
| + | '''Summary of the patent applications from DANA-FARBER CANCER INSTITUTE, INC. on March 21st, 2024''' | ||
| + | |||
| + | The DANA-FARBER CANCER INSTITUTE, INC. has recently filed patents related to novel biomarkers and methods for sensitizing cancer cells to T cell-mediated killing, compounds targeting the Hedgehog signaling pathway for treating cell proliferative disorders, and methods for identifying tumor-specific T-cell clonotypes for adoptive cell transfer in cancer treatment. | ||
| + | |||
| + | Summary in bullet points: | ||
| + | * Patents focus on novel biomarkers and methods to sensitize cancer cells to T cell-mediated killing, compounds targeting the Hedgehog signaling pathway, and methods for identifying tumor-specific T-cell clonotypes for adoptive cell transfer. | ||
| + | * Applications include cancer immunotherapy, personalized medicine for cancer treatment, and drug development for cancer and other cell proliferative disorders. | ||
| + | |||
| + | Notable applications: | ||
| + | * Cancer immunotherapy | ||
| + | * Precision medicine for cancer treatment | ||
| + | * Drug development for cancer and other cell proliferative disorders | ||
| + | |||
| + | |||
| + | |||
| + | |||
==Patent applications for DANA-FARBER CANCER INSTITUTE, INC. on March 21st, 2024== | ==Patent applications for DANA-FARBER CANCER INSTITUTE, INC. on March 21st, 2024== | ||
Latest revision as of 08:29, 27 March 2024
Summary of the patent applications from DANA-FARBER CANCER INSTITUTE, INC. on March 21st, 2024
The DANA-FARBER CANCER INSTITUTE, INC. has recently filed patents related to novel biomarkers and methods for sensitizing cancer cells to T cell-mediated killing, compounds targeting the Hedgehog signaling pathway for treating cell proliferative disorders, and methods for identifying tumor-specific T-cell clonotypes for adoptive cell transfer in cancer treatment.
Summary in bullet points:
- Patents focus on novel biomarkers and methods to sensitize cancer cells to T cell-mediated killing, compounds targeting the Hedgehog signaling pathway, and methods for identifying tumor-specific T-cell clonotypes for adoptive cell transfer.
- Applications include cancer immunotherapy, personalized medicine for cancer treatment, and drug development for cancer and other cell proliferative disorders.
Notable applications:
- Cancer immunotherapy
- Precision medicine for cancer treatment
- Drug development for cancer and other cell proliferative disorders
Contents
- 1 Patent applications for DANA-FARBER CANCER INSTITUTE, INC. on March 21st, 2024
- 1.1 COMPOUNDS FOR TAU PROTEIN DEGRADATION (18200950)
- 1.2 GENERATION OF ANTI-TUMOR T CELLS (18224865)
- 1.3 COMPOUNDS AND METHODS FOR TREATING CANCER (18503556)
- 1.4 METHODS FOR SENSITIZING CANCER CELLS TO T CELL-MEDIATED KILLING BY MODULATING MOLECULAR PATHWAYS (18234229)
- 1.5 C-RAF Mutants that Confer Resistance to RAF Inhibitors (18464360)
- 1.6 MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors (18461820)
Patent applications for DANA-FARBER CANCER INSTITUTE, INC. on March 21st, 2024
COMPOUNDS FOR TAU PROTEIN DEGRADATION (18200950)
Main Inventor
Nathanael S. Gray
GENERATION OF ANTI-TUMOR T CELLS (18224865)
Main Inventor
Catherine J. Wu
COMPOUNDS AND METHODS FOR TREATING CANCER (18503556)
Main Inventor
James Bradner
METHODS FOR SENSITIZING CANCER CELLS TO T CELL-MEDIATED KILLING BY MODULATING MOLECULAR PATHWAYS (18234229)
Main Inventor
Deng Pan
C-RAF Mutants that Confer Resistance to RAF Inhibitors (18464360)
Main Inventor
Caroline Emery
MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors (18461820)
Main Inventor
Levi A. Garraway
